PBPH vs PJP

PBPHBPortfolio Building Block World Pharma and Biotech Index ETF

PJPBInvesco Pharmaceuticals ETF

In short

PBPH Most biotech funds stop at the US border. PBPH buys the developed world's drug complex, pharma and biotech together, through a plain index fund charging 0.13%.

PJP Most pharma ETFs simply own the sector's biggest names. PJP runs a rules-based screen for momentum, quality and value across US drugmakers and holds only the roughly 30 that clear it, for 0.58% a year.

Stated mandate

PBPH The Fund seeks to track, before fees and expenses, the performance of the BITA Global Pharma and Biotech Select Index.

PJP The fund seeks capital appreciation by investing primarily in pharmaceutical companies selected through the Dynamic Pharmaceutical Intellidex Index.

Why people hold it

• PBPH 0.13% a year, in a global thematic aisle where the typical fund charges several times that. Fee drag is about as small as this shelf gets.
• Pharma and biotech under one ticker, global rather than US-only, so overseas drugmakers sit alongside the American names.portfoliobuildingblocketfs.com
• Straight index replication inside an ordinary 1940 Act fund. Published rules do the picking, not a manager's hunch.
• Cheap build plus workable trading puts it among the stronger implementations in its global thematic peer group.

• PJP The Dynamic Pharmaceutical Intellidex screen ranks US drugmakers on momentum, quality and value, so holdings are selected by the numbers rather than by size alone.invesco.com
• Trading since 2005, PJP has run this screen through two decades of patent cliffs, drug-pricing fights and FDA cycles.invesco.com
• A tight book of roughly 30 stocks means the screen's picks carry real weight instead of being diluted across a sprawling sector list. Income arrives quarterly.

Worth knowing

• PBPH One industry, one storyline. Drug pricing rules, patent cliffs and trial readouts swing this basket in ways the broad market does not feel.
• Launched in late 2025, so there is no long live record showing how closely it hugs the index across a full cycle.
• Cash comes back once or twice a year, not monthly. This is an exposure holding, not an income schedule.

• PJP At 0.58% a year the fee sits near the pharma category median, but plain cap-weighted rivals undercut it: XPH at 0.35%, PPH at 0.36%, IHE at 0.37%.
• It trades lighter than the category's heavyweights, so spreads can widen and limit orders matter more here.
• Roughly 30 names in one industry: a single trial readout or patent loss lands harder than it would in a broad healthcare fund.

Full PBPH profile⁠

Full PJP profile⁠